328 related articles for article (PubMed ID: 29040991)
1. Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):583-588. PubMed ID: 29040991
[TBL] [Abstract][Full Text] [Related]
2. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
3. Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.
Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Ida H; Sakurai T; Kitano M; Nishida N; Kudo M
Dig Dis; 2016; 34(6):671-678. PubMed ID: 27750236
[TBL] [Abstract][Full Text] [Related]
4. Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Kitano M; Nishida N; Kudo M
Oncology; 2015; 89 Suppl 2():47-52. PubMed ID: 26584036
[TBL] [Abstract][Full Text] [Related]
5. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).
Kudo M; Arizumi T; Ueshima K; Sakurai T; Kitano M; Nishida N
Dig Dis; 2015 Oct; 33(6):751-8. PubMed ID: 26488473
[TBL] [Abstract][Full Text] [Related]
6. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma.
Wang JH; Kee KM; Lin CY; Hung CH; Chen CH; Lee CM; Lu SN
J Gastroenterol Hepatol; 2015 Feb; 30(2):358-63. PubMed ID: 25088668
[TBL] [Abstract][Full Text] [Related]
7. Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification.
Yamamoto M; Kobayashi T; Hashimoto M; Kuroda S; Kawaoka T; Aikata H; Chayama K; Ohdan H
BMC Cancer; 2021 Jun; 21(1):668. PubMed ID: 34090354
[TBL] [Abstract][Full Text] [Related]
8. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
9. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
[TBL] [Abstract][Full Text] [Related]
10. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Kim JH; Shim JH; Lee HC; Sung KB; Ko HK; Ko GY; Gwon DI; Kim JW; Lim YS; Park SH
Liver Int; 2017 Dec; 37(12):1861-1868. PubMed ID: 28581250
[TBL] [Abstract][Full Text] [Related]
11. A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma.
Hu KS; Tang B; Yuan J; Lu SX; Li M; Chen RX; Zhang L; Ren ZG; Yin X
J Gastroenterol Hepatol; 2019 Nov; 34(11):1984-1991. PubMed ID: 30932246
[TBL] [Abstract][Full Text] [Related]
12. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
[TBL] [Abstract][Full Text] [Related]
15. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
16. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers.
Kimura H; Ohkawa K; Miyazaki M; Sakakibara M; Imanaka K; Tamura T; Sueyoshi H; Takada R; Fukutake N; Uehara H; Ashida R; Ioka T; Nakazawa T; Nakanishi K; Katayama K
Hepatol Int; 2017 Jan; 11(1):105-114. PubMed ID: 27766479
[TBL] [Abstract][Full Text] [Related]
17. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
[TBL] [Abstract][Full Text] [Related]
18. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
19. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
Jun CH; Yoon JH; Cho E; Shin SS; Cho SB; Kim HJ; Park CH; Kim HS; Choi SK; Rew JS
Medicine (Baltimore); 2017 Apr; 96(17):e6745. PubMed ID: 28445298
[TBL] [Abstract][Full Text] [Related]
20. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.
Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Liver Cancer; 2017 Jun; 6(3):227-235. PubMed ID: 28626733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
